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Background: Sarcopenia, the loss ofmusclemass, contributes to various adverse health outcomes in the elderly. It
may be associated with cardiometabolic risk. The aim of this study was to investigate the relationships between
sarcopenia and cardiometabolic risks and to determine an appropriate operational deﬁnition for sarcopenia from
a cardiometabolic perspective.
Material and methods: Using the Korea National Health and Nutrition Examination Survey (KNHANES)
2008–2010 (n = 20,812, ≥20 years old), appendicular skeletal muscle mass (ASM), measured by dual energy
X-ray absorptiometry, divided by height squared (ASM/ht2) or ASMdivided byweight (ASM/wt)were calculated
to deﬁne sarcopenia. Class I or class II sarcopenia was deﬁned as one or two standard deviations, respectively,
below the sex-speciﬁc means of reference values obtained from adults aged 20–29 years.
Results: The respective prevalence rates of class I and class II sarcopenia based on ASM/ht2were 18.6% and 3.5% in
men and 6.1% and 0.2% inwomen. The rates based on ASM/wtwere 25.1% and 4.7% inmen and 23.6% and 5.5% in
women, respectively. The rate of metabolic syndrome and insulin resistance index increased with the severity of
sarcopenia deﬁned by ASM/wt, but there were opposite associations for ASM/ht2 in both sexes. Subjects with
sarcopenia based on the ASM/wt index had higher Framingham 10-year scores and greater risk of cardiovascular
diseases, but these relationships were not provided consistently using the ASM/ht2 measure.
Conclusions: Sarcopenia, deﬁned by the ASM/wt index, but not by ASM/ht2, was signiﬁcantly associated with an
increased risk of cardiometabolic disorders in Korean adults.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
A progressive decrease in muscle mass and an increase in fat mass
are expected compositional changes in the human body with aging
[1]. In these age-related changes, sarcopenia is deﬁned as a condition
characterized by progressive loss of muscle mass and strength, and de-
creased physical performance. Many studies have shown that
sarcopenia can lead to many adverse health outcomes in the elderly,ass; BMI, body mass index; Ht,
ent of insulin resistance; CVD,
he reliability and freedom from
on.
icine, Seoul National University
ang Hospital, 300, Gumi-dong,
.: +82 31 787 7005; fax: +82
.
land Ltd. This is an open access articland given that muscle tissue plays many important biological roles in
glucose and lipid metabolism, sarcopenia may be associated with car-
diovascular and metabolic diseases [2–4].
Decreased serum levels of anabolic hormones, increased levels of
proinﬂammatory cytokines, muscle disuse, accumulated oxidative
stress, and malnutrition have been suggested as contributing factors
for muscle loss in elderly subjects [5,6]. These increased levels of patho-
logicalmarkers are common etiologies in the increased risk ofmetabolic
and cardiovascular diseases (CVDs), therefore, it can be postulated that
sarcopenia might contribute to an increased risk of cardiometabolic dis-
eases in this age group [7,8].
Several studies about the prevalence and clinical issue of sarcopenia
have been carried out in diverse populations [9–11]. Of these deﬁni-
tions, appendicular skeletal muscle mass (ASM) divided by height
squared (ASM/ht2) or by weight (ASM/wt) are representative methods
used when deﬁning that condition [3,12]. These two typical methods,
ASM/wt and ASM/ht2, have been reported to have clinical implications
related to cardiometabolic risks in studies with elderly subjects;
sarcopenia deﬁned using the ASM/ht2 index has provided signiﬁcante under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Recently, we reported that sarcopenia was signiﬁcantly associated with
metabolic syndrome, but that a deﬁnition based on the ASM/wt index
showed closer associations with metabolic impairments than the one
based on ASM/ht2 in a Korean elderly cohort [13]. Thus, it has not yet
been established clearly which diagnostic criteria of sarcopenia could
provide better predictive values for clinical importance in all age groups.
The objective of this study was to investigate the inﬂuences of
sarcopenia on metabolic status and cardiovascular disease in an Asian
ethnic group using a large nationwide survey. We also determined an
appropriate operational deﬁnition for sarcopenia from the perspective
of cardiometabolic disorders.
2. Materials and methods
2.1. Study participants and data collection
The data were derived from the Korea National Health and Nutrition
Examination Survey (KNHANES; http://knhanes.cdc.go.kr/knhanes/
index.do). This is a nationwide, population-based, cross-sectional
study and has been conducted periodically since 1998 by the Division
of Chronic Disease Surveillance of the Korea Centers for Disease Control
and Prevention (KCDC) to assess the health and nutritional status of the
civilian, non-institutionalized population of Korea. It has been conduct-
ed annually since 2008. Here, a stratiﬁed, multistage probability sam-
pling design was used for the selection of household units. Data were
acquired for this study from the results of KNHANES 2008–2010. Regu-
lar exercise was deﬁned as doing some exercise more than three days
per week. Among those who participated in the survey, individuals
aged 20 years and older were included for analysis. Data from people
aged 20–29 years were used as the reference values. Subjects with
any pathological disorders including cancers, liver cirrhosis, chronic
renal insufﬁciency, chronic obstructive lungdiseases, or cerebrovascular
accident were excluded from the analysis. The KNHANES was reviewed
and approved by the Ethics Committee of the KCDC (2008-04EXP-01-C,
2009-01CON-03-2C and 2010-02CON-21-C) and the study was con-
ducted in accordance with the ethical principles of the Declaration of
Helsinki.
2.2. Deﬁnition of metabolic syndrome, Framingham 10-year risk score, and
clinical events of cardiovascular diseases
A diagnosis of metabolic syndrome was deﬁned in cases fulﬁlling at
least three of theﬁve criteria according to themodiﬁedNational Choles-
terol Education Program Adult Treatment Panel III criteria [14] and ab-
dominal obesity based on the Asia Paciﬁc abdominal obesity criteria, a
waist circumference ≥90 cm in men or ≥80 cm in women.
The Framingham 10-year risk score was calculated using age, sex,
smoking status, presence of diabetes mellitus, and measures of systolic
and diastolic blood pressure, total cholesterol, and HDL-cholesterol.
The risk score was then used to calculate the 10-year risk of coronary
heart disease for each individual subject using sex speciﬁc predictive
equations. Very low risk was deﬁned as a risk score of b1%, low risk at
1% ≤10%, moderate risk at 11% ≤20%, and high risk at N20% [15].
A history of clinical events of CVD such as acute myocardial infarc-
tion (AMI) or angina was evaluated as part of the health interview sur-
vey; such events were included in the analysis if a physician had given
the subject a previous diagnosis of AMI or angina.
2.3. Body composition
Whole body and regional body composition were measured by dual
energy X-ray absorptiometry (Discovery W; Hologic, Waltham, MA,
USA) following the manufacturer's protocol as described [16]. Data of
fat and muscle masses in each compartment including the arms, legs,and trunkwere collected. ASMwas calculated as the sumof lean soft tis-
sue in bilateral upper and lower limbs (Fig. S1).
2.4. Criteria for deﬁning sarcopenia
Two different equations were used in this study for deﬁning
sarcopenia: 1) ASM divided by height (m) squared (ASM/ht2) as pro-
posed by Baumgartner et al. [12]; and 2) ASM divided by body weight
(kg) as a percentage of body weight (ASM/wt), modiﬁed from the
study of Janssen et al. [3]. T-scores in each method were then obtained
from the sex-speciﬁc mean values and standard deviations (SDs) in a
young, healthy reference group aged 20–29 years: The T-score was de-
ﬁned as: [subject's (ASM/ht2 or ASM/wt)−mean reference (ASM/ht2
or ASM/wt) / SD of reference (ASM/ht2 or ASM/wt)]. Subjects were cat-
egorized as ‘normal’when the T-score was greater than−1.0 SD below
themean. Class I and class II sarcopeniawere deﬁnedwhen the T-scores
were within−1.0 SD to−2.0 SD below themean, or less than−2.0 SD
below the mean, respectively [3].
2.5. Biochemical analysis
Blood samples were collected from each participant after a fasting
time of 8 h and immediately transported to the Central Testing Institute
in Seoul, Korea. Biochemical measurements, including total cholesterol,
triglycerides, and high-density lipoprotein (HDL) cholesterol were
assessed using an automated analyzer with enzymatic assays (Hitachi
Automatic Analyzer 7600; Tokyo, Japan). Low-density lipoprotein
(LDL) cholesterol levels were calculated by the Friedewald equa-
tion [17]. Fasting insulin levels were measured using IRMA technology
(INS-IRMA; Bio-Source, Nivelles, Belgium). The homeostasis model as-
sessment of insulin resistance (HOMA-IR) was calculated using the fol-
lowing equation [18]: [fasting plasma insulin (mIU/L) × fasting plasma
glucose (mg/dL) × 405].
2.6. Data analysis
All statistical analyses were conducted using the Statistical Package
for the Social Sciences software (version 18, IBM SPSS Statistics; IBM
Corp., Armonk, NY, USA). Data are represented as the mean ± SD. Age
trends of each body composition parameter were estimated using
LOESS curves. Pearson's correlation coefﬁcients were calculated to ex-
plore relationships between muscle mass indices and cardiometabolic
parameters. Multivariable regression analyses with confounding factors
were used to examine the association between sarcopenia deﬁnitions
and HOMA-IR. The prevalence of metabolic syndrome and the Framing-
ham10-year risk scorewas compared between thosewith normalmus-
cle index versus those with class I or class II sarcopenia using chi-
squared tests.
3. Results
3.1. Baseline characteristics of study participants and values of young,
healthy adults
The study design is shown in Fig. S2. A total of 20,812 (9000men and
11,812 women) older than 20 years were ﬁnally included for analysis.
Table 1 lists the baseline characteristics of the study participants and
reference values of young adults aged 20–29 years.
3.2. Age trends of skeletal muscle and fat mass
Data on whole body fat mass, ASM, ASM/ht2, and ASM/wt in age
groups are shown in Fig. 1. Whole body fat mass in men increased
steadily until 30 years of age and then showed a slow and constant
decrease until 90 years of age. In contrast, whole body fat mass in
women showed a rapid increase until 20 years of age and then showed
Table 1
Baseline characteristics of study participants and reference values of young adults aged
20–29 years.
Study participants Young reference group
Men Women Men Women
N 9000 11,812 1047 1433
Age, years (ranges) 48.5 (20–93) 49.1 (20–98) 25.1 (20–29) 25 (20–29)
Height, cm2 169.5 ± 6.7 156.3 ± 6.7 174.6 ± 5.6 161.4 ± 5.5
Weight, kg 69.1 ± 10.9 57.1 ± 9.1 72.2 ± 12.3 56.4 ± 10.1
BMI, kg/m2 23.9 ± 3.1 23.4 ± 3.5 23.7 ± 3.7 21.6 ± 3.6
SBP, mm Hg 119.6 ± 15.9 115.9 ± 18.5 111.7 ± 10.5 102.4 ± 9.5
DBP, mm Hg 77.4 ± 10.5 73.1 ± 10.4 73.7 ± 9.2 67.2 ± 8.4
Fasting glucose,
mg/dL
99.9 ± 24.4 96.2 ± 21.8 88.9 ± 10.7 87.4 ± 12.8
Insulin, mIU/L 9.96 ± 5.81 10.07 ± 5.98 10.69 ± 6.33 10.13 ± 4.51
HOMA-IRa 2.51 ± 2.02 2.45 ± 2.26 2.40 ± 1.79 2.21 ± 1.10
Total cholesterol,
mg/dL
187.2 ± 35.8 188.9 ± 36.3 172.2 ± 32.0 169.1 ± 30.2
Triglyceride, mg/dL 160.5 ± 138.7 115.5 ± 80.7 123.1 ± 115.8 83.9 ± 28.5
HDL-cholesterol,
mg/dL
49.0 ± 11.9 54.4 ± 12.7 51.7 ± 11.5 59.3 ± 12.6
LDL-cholesterol,
mg/dL
112.7 ± 35.6 108.5 ± 35.9 95.1 ± 32.6 83.9 ± 28.5
AST, IU/L 25.1 ± 17.3 20.2 ± 8.6 22.1 ± 15.6 17.0 ± 7.1
ALT, IU/L 26.8 ± 23.5 17.7 ± 13.0 25.9 ± 21.9 13.9 ± 11.5
Hypertension, % 20.5 20.4 2.1 0.2
Diabetes mellitus, % 7.6 6.7 0.3 0.7
Current/ex-/non-
smoker, %
68.9/12.7/18.4 10.0/1.8/88.1 63.7/4.6/31.7 18.6/3.6/77.8
Regular exerciseb, % 21.1 8.0 26.8 8.0
ASM, kg 22.1 ± 3.4 14.4 ± 2.2 24.1 ± 3.3 14.7 ± 2.4
ASM/ht2, kg/m2 7.67 ± 0.91 5.88 ± 0.74 7.90 ± 0.92 5.63 ± 0.78
ASM/wt, % 33.2 ± 2.9 25.4 ± 2.6 33.7 ± 3.1 26.5 ± 2.5
BMI, body mass index; SBP and DBP, systolic and diastolic blood pressure; HOMA-IR, ho-
meostasismodel assessment of insulin resistance; AST andALT, aspartate and alanine ami-
notransferase; ASM, appendicular skeletal muscle mass; ht, height; wt, weight.
a Calculated after excluding the current insulin users (53 for men and 59 for women).
b Regular exercise was deﬁned as doing exercise more than 3 days per week.
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crease. ASM among men increased rapidly until 20 years of age and
then decreased constantly until age 90 with a more rapid loss after the
age of 60 years. However, ASM in women showed a slow increase
until the age of 20 years and then it tended to remain constant until
the age of 50 years in the perimenopausal period, followed by a
decrease. ASM/ht2 showed patterns similar to ASM in men: a rapid
increase until 20 years of age and then a slow decrease until the age
of 60 years followed by an accelerated loss. However, the trend of
ASM/ht2 values among women was discordant with that of ASM. It in-
creased constantly until 60 years of age and then decreased. ASM/wt
index values in men increased sharply until the age of 20 and then de-
creased gradually until age 30, followed with a gentle decline to age
90. ASM/wt in women decreased continuously until 60 years of age,
and then showed a slight rise from then.
3.3. Correlations between BMI and the appendicular skeletal muscle indices
In the simple correlation analyses betweenBMI andASM indices, the
ASM and ASM/ht2 indices showed strong positive associations with BMI
in both men and women (BMI versus ASM, r= 0.604 in men, and r=
0.523 in women; both p b 0.001; BMI versus ASM/ht2, r = 0.749 in
men, and r = 0.733 in women; both p b 0.001). In contrast, ASM/wt
was negatively correlated with BMI in both sexes (r=−0.465 in men
and r=−0.531 in women; both p b 0.001) (Table S1).
3.4. Prevalence of class I and class II sarcopenia in each age group according
to the different deﬁnitions
The prevalence rates of sarcopenia, deﬁned by either ASM/ht2 or
ASM/wt, increased gradually with age in men (Fig. 2A, B). In women,the prevalence of class I and class II sarcopenia deﬁned from ASM/wt
increased until 70–79 years of age with a slight decrease in subjects
aged over that. By contrast, the prevalence of class I sarcopenia deﬁned
by ASM/ht2 showed a decreasing trend with age until 70–79 years and
the overall prevalence of class II sarcopeniawas b0.5% in each age group
(Fig. 2A, B). The respective prevalence rates of class I and class II
sarcopenia based on ASM/ht2 were 18.6% and 3.5% in men and 6.1%
and 0.2% in women. The rates based on ASM/wt values were 25.1%
and 4.7% in men and 23.6% and 5.5% in women, respectively. Using
the cutoff values for class II sarcopenia based on ASM/ht2 values
(6.06 kg/m2 in men and 4.07 kg/m2 in women), the prevalence of
sarcopenia was 9.3% inmen and 0.2% inwomen.When the cutoff values
for class II sarcopenia fromASM/wt were used (27.5% inmen and 21.5%
in women), the prevalence of class II sarcopenia was 10.4% in men and
10.7% in women. The overall distribution of study participants accord-
ing to each deﬁnition is shown in Fig. S3.
3.5. Association of appendicular skeletal muscle indices with HOMA-IR
Without adjustment, the ASM and ASM/ht2 indices were correlated
positively with the HOMA-IR index in both sexes (Table 2). However,
ASM/wt showed a negative correlation with HOMA-IR in both men
and women. These opposite relationships of ASM/ht2 versus ASM/wt
with HOMA-IR remained after adjusting for age (Table 2).
3.6. Prevalence of metabolic syndrome in sarcopenia groups using the
different deﬁnitions
The prevalence of metabolic syndrome in men and women
showed an increasing trend with severity of sarcopenia deﬁned
using the ASM/wt index. In contrast, the trend was reversed when
ASM/ht2 was used, indicating that sarcopenia is associated with a
lower risk of metabolic syndrome (Fig. 3A, B).
3.7. Framingham10-year risk score in sarcopenia groups using the different
deﬁnitions
The severity of sarcopenia deﬁned from either ASM/ht2 or ASM/wt
values was associated with a higher score of the Framingham 10-year
risk assessment in men (Fig. 3C, E). In women, higher scores of the Fra-
mingham 10-year risk assessment with more severe sarcopenia were
also observed when the ASM/wt index was used for the deﬁnition. In
contrast, an opposite trend was observed when the ASM/ht2 index
was used (Fig. 3D, F).
3.8. Risk of cardiovascular diseases in sarcopenia groups using the different
deﬁnitions
Multivariable logistic regression analyses for each sarcopenic group
with the two deﬁnitions were then performed for self-reported clinical
events of CVDs including AMI and angina (Table 3). When the ASM/ht2
indexwas used, only class II sarcopenia inmen andwomen showed sig-
niﬁcantly increased risks for CVDs in the unadjusted model. However,
after adjusting for conventional risk factors, this relationship disap-
peared in men but remained in women. In contrast, men with
sarcopenia based on the ASM/wt criterion had higher risks of CVD in
both the unadjusted and adjusted models. In women, the association
between sarcopenia and CVD was slightly weaker than in men, but
remained signiﬁcant in those with class II sarcopenia after adjusting
for the same variables.
4. Discussions
Cachexia, a pathologic loss of body mass, is known to be associated
with poor outcomes in heart diseases of the elderly [19,20]. In the pres-
ent study using data from KNHANES 2008–2010, sarcopenia, a morbid
Fig. 1. Trends in body composition parameters and ASM indices according to age group inmen (A) and women (B). ASM, appendicular skeletal muscle mass; ht2, height squared (m); wt,
weight (kg).
Fig. 2. Class I and class II sarcopenia based on ASM/ht2 (A) or ASM/wt (B) in each age group. ASM, appendicular skeletal muscle mass; ht2, height squared (m); wt, weight (kg).
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Table 2
Regression analysis between T scores of muscle mass index and HOMA-IR.a
Men Women
β p 95% CI β P 95% CI
Crude
ASM, kg 0.087 b0.001 0.076 0.098 0.105 b0.001 0.095 0.115
ASM/ht2, kg/m2 0.106 b0.001 0.095 0.117 0.136 b0.001 0.126 0.145
ASM/wt, % −0.189 b0.001 −0.201 −0.178 −0.117 b0.001 −0.126 −0.108
Age adjusted
ASM, kg 0.119 b0.001 0.107 0.131 0.127 b0.001 0.117 0.137
ASM/ht2, kg/m2 0.120 b0.001 0.108 0.131 0.129 b0.001 0.119 0.138
ASM/wt, % −0.202 b0.001 −0.214 −0.190 −0.106 b0.001 −0.116 −0.097
ASM, appendicular skeletal muscle mass; BMI, body mass index.
a Values for HOMA-IR were logarithmically transformed.
Fig. 3.Metabolic syndrome (A, B) and Framingham10-year risk scores (C–F) according to sarcopenic severity classiﬁed by ASM/ht2 or ASM/wt indices. ASM, appendicular skeletal muscle
mass; ht2, height squared (m); wt, weight (kg).
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Table 3
Logistic regression of sarcopenia for cardiovascular disease by two different deﬁnitions.
ASM/ht2
Odds ratio (95% CI)
ASM/wt
Odds ratio (95% CI)
Events N Crude p Adjusteda p Events N Crude p Adjusteda p
Men
Normal 43 1 1 24 1 1
Class I sarcopenia 16 1.6 (0.8–2.8) 0.129 1.4 (0.8–2.5) 0.247 33 3.9 (2.3–6.6) 0.001 3.5 (1.7–7.1) b0.001
Class II sarcopenia 5 2.6 (1.0–6.8) 0.040 1.6 (0.5–4.7) 0.388 7 4.5 (1.9–10.5) b0.001 4.0 (1.3–2.5) 0.017
Women
Normal 46 1 1 25 1 1
Class I sarcopenia 2 0.7 (0.2–2.7) 0.580 0.8 (0.2–3.4) 0.796 16 1.9 (1.1–3.6) 0.042 1.5 (0.8–3.0) 0.202
Class II sarcopenia 1 9.5 (1.2–72.6) 0.030 9.5 (1.2–76.8) 0.035 8 4.2 (1.9–9.3) b0.001 2.7 (1.1–6.9) 0.032
ASM, appendicular skeletal muscle mass.
a Adjusted for systolic blood pressure, total-cholesterol, fasting blood glucose levels, and smoking status.
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metabolic syndrome, and CVDs. Of note, sarcopenia deﬁned by the
ASM/wt index was more closely associated with cardiometabolic risks
than that deﬁned by the ASM/ht2 index. This result suggests that
sarcopenia deﬁned by the ASM/wt index might be an appropriate deﬁ-
nition from a cardiometabolic perspective.
Recently, sarcopenia has drawn substantial attention because of its
potential relationship with increased cardiovascular risk and metabolic
impairments [10]. The connection between sarcopenia and CVDs seems
to be mediated by increasing insulin resistance [21]. Because muscle is
the primary tissue contributing towhole body insulin-mediated glucose
disposal, it is conceivable that sarcopenia is an important causal factor in
age-induced insulin resistance and susceptibility to type 2 diabetes [9].
Sarcopenia also shares other pathophysiology such as inﬂammation
and cytokine release with CVDs [22–24].
In the current study, the higher ASM/wt indexwas associatedwith a
better metabolic status whereas that of ASM/ht2 showed inverse
relationships. Furthermore, the Framingham 10-year risk scores had
positive correlations with the severity of sarcopenia deﬁned by the
ASM/wt index in both men and women, but negative correlations
with the ASM/ht2 index inwomen. In the association of sarcopenic indi-
ces with comorbid CVDs including AMI and angina, only the ASM/wt
index showed a signiﬁcant stepwise increase of CVDs with the severity
of sarcopenia, after adjusting for confounding factors in both sexes.
These phenomena are in linewith other reports suggesting that the def-
inition of sarcopenia based on theASM/ht2 indexmight not be appropri-
ate for estimating increased risks of clinical consequences [25–28].
As shown in Supplemental Table 1, the ASM/ht2 index is strongly
correlated with BMI in both men and women. This means that the
ASM/ht2 index may misclassify those subjects who have a higher BMI
because of higher fat mass into the non-sarcopenic group. This pattern
was previously observed in another study [25]. In this context, the
ASM/ht2 index is not likely to indicate the metabolic risks of given indi-
viduals, whereas the ASM/wt index appears to reﬂect the cardiometa-
bolic risks more accurately.
In this study, the associations between sarcopenia and clinical conse-
quences such as CVDsweremuch stronger inmen than those inwomen
as with other studies [11,29]. This difference might be partially
explained by the lower rate of cardiometabolic diseases in women.
Moreover, testosterone has a decisive inﬂuence on muscle size and
muscle strength in men, but estrogens modulate fat tissue dominantly
and have relatively neutral or negative effects on muscle mass increase
[30–32]. Therefore, these distinguishable effects of sex hormones on
muscle tissue might also contribute to the gender discrepancy in
terms of loss of muscle mass with age.
In this study, the prevalence of sarcopenia as deﬁned by the ASM/wt
index increasedwith aging, which is predictable and biologically plausi-
ble. In contrast, the prevalence of sarcopenia deﬁned by the ASM/ht2
index in women declined with aging, suggesting that this measuredoes not reﬂect the nature of age-related muscle loss accurately. In
addition, the prevalence of sarcopenia differed markedly according to
the diagnostic criteria. The cutoff values for sarcopenia based on the
ASM/ht2 index were 6.06 kg/m2 for men and 4.07 kg/m2 for women;
these were lower than ﬁgures from American populations, and similar
in men and lower in women when compared with data from Chinese
groups (Table S2) [1,12]. Consequently, the prevalence of sarcopenia
based on ASM/ht2 (9.3% for men and 0.2% for women) was lower in
these Korean subjects than in other ethnic groups, especially in
women (Table S2) [33,34]. Given that aging is commonly accompanied
by body compositional changes in both sexes, the 0.2% prevalence of
sarcopenia in women deﬁned from the ASM/ht2 index seems to be too
low. In contrast, the prevalence of sarcopenia acquired from the cutoff
values in ASM/wt was 10.4% for men and 10.7% for women, which is
similar to results from the Chinese groups and slightly higher than
among white populations [3,33]. Thus, sarcopenia deﬁned by ASM/wt
seems to be better at predicting cardiometabolic risk than that deﬁned
by ASM/ht2.
The present study had several strengths. We used a large, represen-
tative, nationwide survey. Furthermore, various assessment tools in-
cluding the Framingham risk score which provided strong associations
with other risk factor for CVDs in Koreans were used for evaluating car-
diometabolic risks [35,36]. However, there were also several limitations
in this study. First, the cross-sectional design of this studymeant thatwe
were not able to determine whether sarcopenia could affect the inci-
dence of cardiovascular events ormortality. Second, we did not evaluate
individual muscle strength or physical performance. Third, CVD events
were retrieved from self-reported questionnaires, which is appropriate
given the nature of the national survey data. However, the Korean Na-
tional Health Insurance Database, a national database for medical insur-
ance, which engages 97% of clinics and hospitals in Korea, also reported
similar CVD event rateswith that of this survey [37]. Fourth, this dataset
is representative of the Korean population and the current study ﬁnd-
ings can be applicable to other Asian groups with similar anthropomet-
ric and metabolic proﬁles [38].5. Conclusions
Sarcopenia is signiﬁcantly associated with metabolic impairment
and increased risks of cardiovascular disorders particularly in the elder-
ly. The concept of sarcopenia deﬁned as appendicular skeletal muscle
mass adjusted for weight (ASM/wt) might be better for predicting
these cardiometabolic burdens than that adjusted for height squared
(ASM/ht2). Longitudinal studies are warranted to investigate the role
of sarcopenia based on this deﬁnition in predicting the cardiometabolic
consequences. We propose that a multidisciplinary collaboration in this
research ﬁeld and our approach could offer guidance for future research
into sarcopenia from a cardiometabolic perspective.
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